

Robbins Andrew R  
Form 4  
December 19, 2017

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Robbins Andrew R

2. Issuer Name and Ticker or Trading Symbol  
ARRAY BIOPHARMA INC  
[ARRY]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
12/16/2017

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
\_\_\_\_ 10% Owner  
\_\_\_\_ Other (specify below)  
COO

C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

BOULDER, CO 80301

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|---|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                   |   |
| Common Stock                    | 12/16/2017                           |  | M                              |   | 13,082 <sup>(1)</sup>   | A  | \$ 0 49,766 <sup>(2)</sup>        | D |
| Common Stock                    | 12/16/2017                           |  | F                              |   | 6,094 <sup>(3)</sup>  | D  | \$ 10.92 43,672                   | D |
| Common Stock                    | 12/18/2017                           |  | M                              |   | 200,000   | A  | \$ 5.14 243,672 <sup>(4)</sup>    | D |
| Common Stock                    | 12/18/2017                           |  | M                              |   | 20,366  | A  | \$ 4.91 264,038 <sup>(4)</sup>    | D |
| Common Stock                    | 12/18/2017                           |  | M                              |   | 89,634  | A  | \$ 4.91 353,672 <sup>(4)</sup>    | D |

Edgar Filing: Robbins Andrew R - Form 4

|              |            |                  |         |   |          |                        |   |
|--------------|------------|------------------|---------|---|----------|------------------------|---|
| Common Stock | 12/18/2017 | M                | 87,500  | A | \$ 4.63  | 441,172 <sup>(4)</sup> | D |
| Common Stock | 12/18/2017 | S <sup>(5)</sup> | 282,874 | D | \$ 10.72 | 158,298                | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Underlying Security (Instr. 3 and 4) |            |              |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|------------|--------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date                                   | Title      |              |
| Restricted Stock Units                     | \$ 0   | 12/16/2017                           |  | M                              |   | 13,082   | <sup>(7)</sup>                                    | 12/16/2020 | Common Stock |
| Restricted Stock Units                     | \$ 0   | 12/16/2017                           |  | A                              |   | 55,875   | <sup>(9)</sup>                                    | 12/17/2021 | Common Stock |
| Stock Option (Right to Buy)                | \$ 10.92   | 12/16/2017                           |  | A                              |   | 335,250  | <sup>(10)</sup>                                   | 12/16/2027 | Common Stock |
| Stock Option (Right to Buy)                | \$ 5.14  | 12/18/2017                           |  | M                              |   | 200,000  | <sup>(11)</sup>                                   | 07/31/2022 | Common Stock |
| Stock Option (Right to Buy)                | \$ 4.91  | 12/18/2017                           |  | M                              |   | 20,366   | 07/23/2017  | 03/28/2023 | Common Stock |
| Stock Option (Right to Buy)                | \$ 4.91  | 12/18/2017                           |  | M                              |   | 89,634   | <sup>(12)</sup>                                   | 03/28/2023 | Common Stock |
| Stock Option                               | \$ 4.63  | 12/18/2017                           |  | M                              |   | 87,500   | <sup>(13)</sup>                                   | 04/01/2024 | Common Stock |

(Right to Buy)

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Robbins Andrew R<br>C/O ARRAY BIOPHARMA INC.<br>3200 WALNUT ST<br>BOULDER, CO 80301 |               |           | COO     |       |

## Signatures

Jason Haddock, attorney-in-fact for Andrew R. Robbins 12/19/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs.
- (10) The option vests in four equal annual installments beginning on December 16, 2018.
- (11) The option vested in four equal annual installments beginning on July 23, 2013.
- (12) The option vested in four equal annual installments beginning on July 23, 2014.
- (13) The option vested in four equal annual installments beginning on April 1, 2015.
- (2) Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
- (3) Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- (4) Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
- (5) These trades were made pursuant to a Rule 10b5-1 trading plan.
- (6) The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
- (7) The RSUs vested on December 16, 2017.
- (8) Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person.
- (9) Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.